Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood's tiny messengers may expose hidden brain injury

NCT ID NCT07769294

Knowledge-focused Sponsor: Roberto Furlan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study investigates whether tiny particles called extracellular vesicles, released by brain cells into the blood, can serve as reliable markers of nerve damage in people with multiple sclerosis or stroke. Researchers will measure these particles in blood samples from 60 participants to see if they reflect ongoing brain injury better than current tests. The goal is to develop a simpler way to monitor neurodegenerative processes, which could speed up the development of new treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Measurement of neural extracellular vesicles in blood plasma (no drug or treatment given)
What this could lead to
If successful, this could lead to a simple blood test to monitor nerve damage in multiple sclerosis and stroke, helping to develop new treatments faster.
What could go wrong
This is an early exploratory study with a small number of participants. The biomarkers may not prove specific or reliable enough for clinical use, and the technology is still being developed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participating subjects will be recruited among the population admitted to IRCCS Ospedale San Raffaele in Milan, Italy, or to IRRCS Fondazione Santa Lucia in Rome, Italy, and attending either the Multiple sclerosis Center or the Stroke Unit.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For multiple sclerosis: age 18-50 years old; diagnosis of relapsing-remitting Multiple Sclerosis (3). No steroid treatment at enrolment and in the 3 months before. For stroke: age \>18 years, diagnosis of ischemic stroke and presented within 24h from symptoms onset . Exclusion Criteria: For multiple sclerosis: any other neurological or autoimmune disease; any previous disease modifying treatment. For stroke: signs or symptoms of infection on admission, or a history of immunological, haematological disease, or previous neurological disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke multiple sclerosis relapsing-remitting multiple sclerosis stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.